Statin Treatment and the Natural History of Atherosclerotic-Related Diseases: Pathogenic Mechanisms and the Risk-Benefit Profile

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|10|4|425-432

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.10, Iss.4, 2004-02, pp. : 425-432

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cardiovascular Risk-Benefit Profile of Sibutramine

By Scheen A.J.  

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 5, 2010-10 ,pp. : 321-334

Adis International

Access to resources Recommend Favorite

Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia

By Penzak Scott R   Chuck Susan K  

Expert Opinion on Drug Safety, Vol. 1, Iss. 1, 2002-05 ,pp. : 5-17

Informa Healthcare

Access to resources Recommend Favorite

A Risk-Benefit Analysis of Methadone Maintenance Treatment

By Bell J.  

Drug Safety, Vol. 22, Iss. 3, 2000-03 ,pp. : 179-190

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Sildenafil in the Treatment of Erectile Dysfunction

By Vitezic D.  

Drug Safety, Vol. 24, Iss. 4, 2001-01 ,pp. : 255-265

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Alendronate in the Treatment of Involutional Osteoporosis

By Devogelaer J-P.  

Drug Safety, Vol. 19, Iss. 2, 1998-08 ,pp. : 141-154

Adis International

Access to resources Recommend Favorite